Ultra Orphan Validation Process

SMC Executive has recently agreed an update to the ultra-orphan validation process such that from 1st September, ultra-orphan validation decisions will expire after 2 years. Thereafter if a product has MHRA marketing authorisation; if there are eligible patients in NHSScotland; and if no submission is forthcoming, SMC will move to issue Not Recommended advice.

Back to latest updates